VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
